A novel “shock and kill” strategy for eliminating Mtb persisters in the CD4 T-cell-deficient host

Location

Baltimore, Maryland

Dates

02/01/2016 - 12/31/2019

PI

Petros Karakousis, MD

The objective of this study is to determine if pharmacological inhibition of the Mtb stringent response leads to accelerated eradication of TB infection in CD4-deficient mice. The structure activity relationship of various RelMtb inhibitors is being explored.

Projects

Decentralized testing for tuberculosis with...

This is a highly pragmatic cluster randomized trial to compare the impact, implementation, and cost-effectiveness of on-site...

Read More

Impact of diabetes on TB treatment outcomes...

This is a study to prospectively enroll and follow TB patients co-infected with diabetes and TB patients without diabetes...

Read More

TB Modeling and Analysis Consortium

The TB MAC brings TB modelers together from a wide range of institutions to answer questions of global policy relevance.  I...

Read More

mHealth for improved TB contact investigation...

This multicenter randomized study is evaluating the implementation, effectiveness, cost-effectiveness, and population-level...

Read More

Statins as Adjunctive, Host-Directed Therapy...

The goal of this study is to investigate the potential utility of pravastatin as an adjunctive, host-directed therapy for...

Read More